Addition of moxifloxacin to the recommended regimen improves clinical outcomes of the non-drug resistant TB, says a latest study published in International Journal of Infectious Diseases. Moreover, moxifloxacin does not cause more adverse events during treatment and also reduces tuberculosis recurrence after treatment. The currently implemented regimen for pulmonary TB comprises the combination of isoniazid (H), rifampicin (R), pyrazinamide (Z), and ethambutol (E) for 2 months and isoniazid plus rifampicin for the following 4 months.
There have been several reports that use of moxifloxacin in addition to the recommended regimens is beneficial for TB treatment, but the results remain inconsistent. Therefore, to determine the role of moxifloxacin in the treatment of TB, a meta-analysis of all available studies was performed to comprehensively investigate the efficacy and safety of…
